Biopharma thought leadership

In the production of monoclonal antibodies (mAbs), finding ways to remove bottlenecks and improve yields in downstream processing continues to be a key focus area for biopharma manufacturers.

COVID-19 has compressed bioprocessing timelines, leaving no room for uncertainty in the characterization of raw materials and contaminants

Single-use systems have come a long way. Timothy Korwan and Sean DeFusco, single-use experts from Avantor, discuss biopharma’s experience with the technology so far – and consider why it has become a popular choice for producing new drugs.

There has been significant change across the biomanufacturing industry over the last couple of decades, as increased complexity of biologics and a growing focus on smaller patient populations have led to a greater need for cost control and process efficiency.

Scaling up cell & gene therapies from research and development to commercialization is creating a new set of challenges for manufacturers...

Scaling up cell & gene therapies from research and development to commercialization is creating a new set of challenges for manufacturers...

It is common for biologics manufacturing processes to require hundreds of raw materials, ranging from media and media supplements, buffers, and salts to other process chemicals...

As the biopharmaceutical industry sharpens its focus on gene therapy, opportunities for advancements and challenges in manufacturing processes still remain. Dr. Ger Brophy, executive vice president of biopharma production at Avantor, offers insights on how the biopharma industry can evolve its processes through lessons learned from manufacturing monoclonal antibodies (mAbs) or vaccines, improving supplier collaboration, and other factors.

The term “optimize” is often applied to complex manufacturing, automation and business processes and implies that the most efficient function of all the elements of a process – technologies, sequences and procedures – has not been achieved...

With the rapid growth of single-use systems (SUS) for drug production, especially by drug manufacturers with multiple locations across the globe, there are many risks associated with underestimating the regulatory compliance, manufacturing and quality requirements of these systems...

Despite significant advances made in recent years to increase biologic yields as well as the intensity and consistency of these processes, there is still the potential for innovation in this area in order to reach more efficient production of therapeutic proteins...

Continued expansion of the biosimilar marketplace has led to many commercial opportunities and technical challenges...

Processing times can be reduced and yields increased by utilizing new hydrophobic interaction chromatography tools.

Q&A interview with Ger Brophy, Executive Vice President for Biopharma Production at Avantor.